Aptamers and the Blood-Brain Barrier

26 August 2016

Aptamers have emerged as an exciting and promising new means of treating neurological disease, with the potential to fundamentally change the way we approach CNS-targeted therapeutics. With the propensity to cross the blood–brain barrier (BBB), Aptamers can target specific cell or signalling systems, respond to endogenous stimuli, or act as vehicles for gene […]

Aptamers and Cancer Immunotherapy

08 June 2016

The immune system plays a vital role in suppressing and eliminating cancer. Immunotherapeutics targeting tumour cell biology has become a popular field of biomedicine and there remains a great deal of excitement surrounding this. The emergence of antibody therapies against molecular regulators including CTLA-4 and PD-1 have shown positive results in clinical trials […]